Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products and other therapies. Co.'s diabetes products include: Basaglar®, a long-acting human insulin analog for the treatment of diabetes; and Trajenta®, for the treatment of type 2 diabetes. Co.'s oncology products include: Alimta®, for treatment of patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations. We show 54 historical shares outstanding datapoints in our LLY shares outstanding history coverage, used to compute LLY market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing Eli Lilly market cap history over the course of time is important for investors
interested in comparing Eli Lilly's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of Eli Lilly versus a peer is one thing; comparing
Eli Lilly market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like Eli Lilly can fluctuate over the course of history.
With this page we aim to empower investors researching Eli Lilly by allowing them to research the Eli Lilly market cap history. |
Free LLY Email Alerts:
Video: The Importance of Market Cap
